Results 181 to 190 of about 2,159,893 (336)

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Correction: TSG101 depletion dysregulates mitochondria and PML NBs, triggering MAD2-overexpressing interphase cell death (MOID) through AIFM1-PML-DAXX pathway

Cell Death and Disease
Yao Xi, Rui Xu, Shengnan Chen, Jiezhu Fang, Xiang Duan, Yidan Zhang, Guoli Zhong, Zhifei He, Yan Guo, Xinyu Li, Wenzhi Tao, Yang Li, Yan Li, Lei Fang, Yohei Niikura   +14 more
doaj   +1 more source

The function of Toll-like receptor 2 in control of transcriptome responses to the microbiome and microbiome composition. [PDF]

Anim Microbiome
Liu L, Spaink HP.
europepmc   +1 more source

Transposon Mutagenesis of Planctomyces limnophilus and Analysis of a pckA Mutant

, 2012
Harold J. Schreier, Wipawee Dejtisakdi, Jose Ortega Escalante, Marina Brailo   +3 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Mutant p53: evolving perspectives. [PDF]

Genes Dev
Efe G, Cunningham K, Rustgi AK, Prives C, Manfredi JJ, Sánchez-Rivera FJ.   +5 more
europepmc   +1 more source

Mutant mice galore [PDF]

Nature, 2007
openaire   +2 more sources

PUB147 KRAS Mutants Regulated PD-L1 Expression through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells [PDF]

, 2017
Rong Guo, Jie Wang, Hua Bai
openalex   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Portraits of clonal hematopoiesis in DNMT3A/TET2/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia. [PDF]

Ann Hematol
Patel SA, Khedr S, Hutchinson L, Xie Y, Khouri MR, Cerny J, Gerber JM.   +6 more
europepmc   +1 more source